ypTNM category combined with AJCC tumor regression grade for screening patients with the worst prognosis after neoadjuvant chemoradiation therapy for locally advanced rectal cancer

Figures & data

Table 1 Baseline clinical characteristics and treatment results of the study population

Characteristics	Value
Median age (range), years	55 (22–82)
Sex, n (%)
Female	88 (33.2)
Male	177 (66.8)
Median distal tumor margin from anal Verge (range), cm	6 (2–13)
Clinical T category, n (%)
cT2	5 (1.9)
cT3	114 (43.0)
cT4	146 (55.1)
Clinical N category, n (%)
cN0	74 (27.9)
cN1	91 (34.3)
cN2	100 (37.7)
Operative procedure, n (%)
Miles	96 (36.2)
Dixon	165 (62.2)
Others	4 (1.5)
Pathological T category, n (%)
ypT0	68 (25.7)
ypT1	10 (3.8)
ypT2	47 (17.7)
ypT3	125 (47.2)
ypT4	15 (5.7)
Pathological N category, n (%)
ypN0	201 (75.8)
ypN1	50 (18.9)
ypN2	14 (5.3)
TRG, n (%)
TRG0	68 (25.7)
TRG1	51 (19.2)
TRG2	127 (47.9)
TRG3	19 (7.2)

Note: Miles, abdominal perineal resection; Dixon, low anterior resection.

Abbreviations: TRG, tumor regression grade; ypN, postsurgical pathological N category; ypT, postsurgical pathological T category.

Table 2 Univariate survival analysis of patients according to different factors

Factor							5-year survival (%)
	OS	P-value	95% CI	DFS	P-value	95% CI	RFS	P-value	95% CI	MFS	P-value	95% CI
All patients	79.4			68.8			94.4			76.5
Pathological T stage
ypT0	93.8	<0.001	1.291–2.053	85.0	<0.001	1.320–1.955	95.4	0.065	0.888–2.288	92.6	<0.001	1.481–2.535
ypT1	100			90.0			100			90.0
ypT2	89.4			82.9			97.6			91.1
ypT3	67.3			54.8			93.1			62.0
ypT4	66.0			53.3			83.9			64.6
Pathological N stage
ypN0	86.2	<0.001	1.592–3.097	77.1	<0.001	1.696–3.029	95.5	0.159	0.902–3.981	84.6	<0.001	1.906–3.672
ypN1	58.9			45.3			93.3			51.9
ypN2	50.6			34.3			83.1			47.6
AJCC-TRG
TRG0	93.8	0.003	1.181–2.053	85.0	0.011	1.142–1.812	95.4	0.092	0.868–2.994	92.6	0.004	1.179–2.068
TRG1	81.2			67.8			97.4			73.8
TRG2	70.8			61.6			94.7			69.1
TRG3	78.9			59.9			77.1			73.0
ypT+AJCC-TRG
ypT0+TRG0	93.8	<0.001	1.281–1.864	85.0	<0.001	1.244–1.678	95.4	0.096	0.916–1.893	92.6	<0.001	1.434–2.288
ypT1–2+TRG1	90.9			76.8			94.7			85.6
ypT1–2+TRG2–3	91.4			88.6			100			94.0
ypT3–4+TRG1	73.9			61.2			100			65.0
ypT3–4+TRG2–3	65.3			52.9			90.1			61.5
ypN+AJCC-TRG
ypN0+TRG0–1	91.8	<0.001	1.407–2.119	82.9	<0.001	1.382–1.964	95.8	0.509	0.886–2.201	89.0	<0.001	1.537–2.345
ypN0+TRG2–3	80.4			71.1			95.2			79.7
ypN1–2+TRG0–1	64.8			44.9			94.7			61.4
ypN1–2+TRG2–3	54.1			41.7			89.2			46.3

Abbreviations: AJCC-TRG, American Joint Committee on Cancer-tumor regression grade; DFS, disease-free survival; MFS, distant-metastasis-free survival; OS, overall survival; RFS, local-recurrence-free survival; ypN, postsurgical pathological N category; ypT, postsurgical pathological T category.

Figure 1 Results of follow-up evaluations among different ypT subgroups.

Notes: (A) OS. (B) DFS.

Abbreviations: OS, overall survival; DFS, disease-free survival; ypT, postsurgical pathological T category.

Figure 2 Results of follow-up evaluations among different ypN subgroups.

Notes: (A) OS. (B) DFS.

Abbreviations: OS, overall survival; DFS, disease-free survival; ypN, postsurgical pathological N category.

Figure 3 Results of follow-up evaluations among different ypT+AJCC-TRG subgroups.

Notes: (A) OS. (B) DFS.

Abbreviations: AJCC-TRG, American Joint Committee on Cancer-tumor regression grade; OS, overall survival; DFS, disease-free survival; ypT, postsurgical pathological T category.

Figure 4 Results of follow-up evaluations among different ypN+AJCC-TRG subgroups.

Notes: (A) OS. (B) DFS.

Abbreviations: AJCC-TRG, American Joint Committee on Cancer-tumor regression grade; OS, overall survival; DFS, disease-free survival; ypN, postsurgical pathological N category.